Tag: Continuous Glucose Monitor (CGM)
Henry Schein expands supplies platform with Acentus
November 20, 2024HME News Staff
MELVILLE, N.Y. - Henry Schein has signed an agreement to buy Tampa, Fla.-based Acentus, a national supplier specializing in delivering continuous glucose monitors (CGMs) with $35 million in annual revenue.
Along with its previous acquisitions of Prism Medical Products in 2021 and Shield Healthcare and Mini Pharmacy in 2023, Henry Schein now expects its home medical supply platform to have annual revenue of about $35 million.
“As the delivery of health care in the U.S. is increasingly...
Abbott opens new facility for sensors, CGMs
November 18, 2024HME News Staff
ABBOTT PARK, Ill. – Abbott on Nov. 18 held a ceremony to celebrate the official opening of a state-of-the-art manufacturing facility in Kilkenny, Ireland, part of its €440 million investment in the country. The new 30,000-square-meter Kilkenny facility is producing FreeStyle Libre 3 sensors and the latest generation in Abbott’s continuous glucose monitoring portfolio for people living with diabetes. "This is our latest commitment to providing innovative care and supporting...
FDA says OK to leave FreeStyle Libre CGMs on for imaging
October 30, 2024HME News Staff
ABBOTT PARK, Ill. – Users of the FreeStyle Libre 2 and 3 continuous glucose monitoring systems from Abbott no longer need to remove and discard the devices for imaging procedures, such as X-rays, CT scans and MRIs. The U.S. Food and Drug Administration has cleared the removal of the imaging contraindication, making Abbott’s systems the first and only patient-applied CGM sensors approved for these screenings. "For people with diabetes, especially those using insulin, removing a CGM...
In brief: Hurricane waivers, NIV advocacy, CRT lobby
October 4, 2024HME News Staff
WASHINGTON – CMS will permit people with Medicare who have lost or had damage to their DMEPOS products because of Hurricane Helene to receive replacements of such items and services, according to a bulletin from AAHomecare.
Specifically, CMS waivers for Florida, Georgia, North Carolina, South Carolina, and Tennessee state that:
When DMEPOS is lost, destroyed, irreparably damaged, or otherwise rendered unusable, CMS is allowing DME MACs to have the flexibility to waive...
AAH strengthens NIV, CGM advocacy
October 3, 2024HME News Staff
WASHINGTON – AAHomecare has expanded its relationship with legal and public policy firm Foley Hoag to strengthen its advocacy work on significant coverage issues for non-invasive ventilators and continuous glucose monitors. “Foley Hoag’s expertise in Medicare and Medicaid policy is already helping us sharpen our arguments by identifying established laws and regulations that support our advocacy goals,” said Tom Ryan, president and CEO of AAHomecare. “In addition, their...
Ascensia launches Eversense 365
October 3, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care has launched its Eversense 365 continuous glucose monitoring system, which received clearance from the U.S. Food and Drug Administration in September. “Eversense offers a completely differentiated CGM experience, overcoming many of the frustrations experienced with traditional, short-term CGMs, such as early failure, disruptive false alerts and skin irritation,” said Brian Hansen, president of CGM at Ascensia. “With only one CGM replacement...
CCS: ‘There’s something about that DME interaction’
September 27, 2024Theresa Flaherty, Managing Editor
DALLAS – People with diabetes fall off their therapy all the time for a variety of reasons, but DME providers are best equipped to catch them when they do, according to the results of a new study conducted by CCS.
DME patients reinitiated their use of continuous glucose monitors 22% of the time compared to 10% of pharmacy patients, the study found.
“I didn’t expect the difference to be that big,” said Dr. Arti Masturzo, chief medical officer at CCS. “People...
In brief: CGM outcomes, Vent360+ launch, O&P WOY, AdaptHealth refi
September 18, 2024HME News Staff
DALLAS – Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy benefit, according to peer-reviewed research conducted by CCS and published in the Journal of Medical Internet Research Diabetes (JMID).
Non-adherent patients who use CGMs also had a higher rate of therapy reinitiation when therapy was provided through a medical (22%) vs. pharmacy...
Study: Using medical benefit can result in positive outcomes
September 17, 2024HME News Staff
DALLAS – Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy benefit, according to peer-reviewed research conducted by CCS and published in the Journal of Medical Internet Research Diabetes (JMIR Diabetes).
Non-adherent patients who use CGMs also had a higher rate of therapy reinitiation when therapy was provided through a medical (22%) vs....
Senseonics, Ascensia launch one-year CGM system
September 17, 2024HME News Staff
GERMANTOWN, Md., and PARSIPPANY, N.J. – Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system. “The approval of Eversense 365 represents a significant leap in CGM innovation,” said Tim Goodnow, PhD, president and CEO of Senseonics. “Extending sensor longevity to a full year, coupled with seamless device connectivity and a high level of accuracy, provides...